目的（a）通过英国进行的≥50岁的女性乳腺筛查计划（每3年进行1次筛查）,比较用硬拷贝图像阅读的全数字乳腺成像（FFDM）与荧光胶片乳腺成像（SFM）的表现；（b）对发表的资料与英国的数据行Meta分析。方法该研究符合英国国家健康服务...目的（a）通过英国进行的≥50岁的女性乳腺筛查计划（每3年进行1次筛查）,比较用硬拷贝图像阅读的全数字乳腺成像（FFDM）与荧光胶片乳腺成像（SFM）的表现；（b）对发表的资料与英国的数据行Meta分析。方法该研究符合英国国家健康服务中心办公室研究伦理委员会（UK National Health Service Central Office for Research Ethics Committee）的指导方针：因为是匿名资料的回顾性分析．无需告知病人。自2006年1月-2007年6月,筛查中心对8478名伦敦人进行了FFDM筛查,对31720人进行了SFM筛查。展开更多
Objectives: To evaluate the performance of a strategy in which, after immunoreactive trypsinogen (IRT) determination, genetic analysis is replaced by a biological test, the pancreatitis-associated protein (PAP) enzyme...Objectives: To evaluate the performance of a strategy in which, after immunoreactive trypsinogen (IRT) determination, genetic analysis is replaced by a biological test, the pancreatitis-associated protein (PAP) enzyme-linked immunosorbent assay (ELISA). Study design: The French newborn screening program includes cystic fibrosis (CF) screening by the IRT/CFTR mutation strategy. PAP was assayed on screening cards, in parallel with IRT, in all newborns from 5 French regions (n = 204,749). Analysis of PAP values in CF and non-CF newborns with elevated IRT allowed direct comparison between the current strategy and the proposed IRT/PAP strategy. Results: A protocol in which newborns with IRT >50 ng/mL and PAP >1.8 ng/mL and those with IRT >100 ng/mL and PAP >1.0 ng/mL are directly recalled for sweat testing would have the same performance as the IRT/CFTR mutation strategy. Conclusions: The IRT/PAP strategy is an alternative for CF newborn screening, which avoids the drawbacks of genetic analysis and is cheaper and easier to implement than the current IRT/CFTR mutation strategy.展开更多
文摘目的（a）通过英国进行的≥50岁的女性乳腺筛查计划（每3年进行1次筛查）,比较用硬拷贝图像阅读的全数字乳腺成像（FFDM）与荧光胶片乳腺成像（SFM）的表现；（b）对发表的资料与英国的数据行Meta分析。方法该研究符合英国国家健康服务中心办公室研究伦理委员会（UK National Health Service Central Office for Research Ethics Committee）的指导方针：因为是匿名资料的回顾性分析．无需告知病人。自2006年1月-2007年6月,筛查中心对8478名伦敦人进行了FFDM筛查,对31720人进行了SFM筛查。
文摘Objectives: To evaluate the performance of a strategy in which, after immunoreactive trypsinogen (IRT) determination, genetic analysis is replaced by a biological test, the pancreatitis-associated protein (PAP) enzyme-linked immunosorbent assay (ELISA). Study design: The French newborn screening program includes cystic fibrosis (CF) screening by the IRT/CFTR mutation strategy. PAP was assayed on screening cards, in parallel with IRT, in all newborns from 5 French regions (n = 204,749). Analysis of PAP values in CF and non-CF newborns with elevated IRT allowed direct comparison between the current strategy and the proposed IRT/PAP strategy. Results: A protocol in which newborns with IRT >50 ng/mL and PAP >1.8 ng/mL and those with IRT >100 ng/mL and PAP >1.0 ng/mL are directly recalled for sweat testing would have the same performance as the IRT/CFTR mutation strategy. Conclusions: The IRT/PAP strategy is an alternative for CF newborn screening, which avoids the drawbacks of genetic analysis and is cheaper and easier to implement than the current IRT/CFTR mutation strategy.
